| Multiple Sclerosis |
1 |
1 |
| Monoclonal Antibody |
0 |
0.71 |
| Immunization |
0 |
0.98 |
| Receptors |
0 |
0.47 |
| COVID-19 Vaccine |
0 |
0.99 |
| Health Care Quality, Access, and Evaluation |
0 |
0.95 |
| Biologic Therapy |
0 |
0.33 |
| Health Care Access |
0 |
0.33 |
| COVID-19 |
0 |
0.9 |
| Vaccines |
0 |
0.85 |
| Antineoplastic Drug |
0 |
0.24 |
| Biosimilars |
0 |
0.24 |
| Food and Drug Administration (FDA) |
0 |
0.75 |
| Immunocompromise |
0 |
0.7 |
| Social Determinants of Health |
0 |
0.07 |